GlassScriptPhysician profile
Monica Crawford
NPI 1225243603
$5,318.90
in general payments reported to CMS, 2019-2025
25 companies · $267 in 2025
The $267 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,123 · 2020: $718 · 2021: $699 · 2022: $897 · 2023: $888 · 2024: $728 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,882.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,988.35 | 2019-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $815.74 | 2019-2025 | Cimzia, Bimzelx |
| Amgen INC. | $425.72 | 2019-2025 | Otezla, Enbrel, Otezla |
| Pfizer INC. | $371.80 | 2019-2025 | |
| Lilly USA, LLC | $345.08 | 2019-2024 | Taltz |
| Horizon Therapeutics Plc | $235.65 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $228.90 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $159.92 | 2022-2024 | Saphnelo |
| Mallinckrodt Enterprises LLC | $128.71 | 2019 | |
| Glaxosmithkline, LLC. | $115.25 | 2019-2023 | Benlysta |
| Radius Health, INC. | $103.81 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $57.95 | 2019 | |
| Janssen Biotech, INC. | $56.07 | 2019-2021 | |
| Celgene Corporation | $50.27 | 2019 | |
| Mallinckrodt Hospital Products INC. | $40.19 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $35.55 | 2019 | |
| Genentech USA, INC. | $23.76 | 2019 | |
| Ani Pharmaceuticals, INC. | $23.35 | 2024 | Purified Cortrophin Gel |
| Genzyme Corporation | $20.00 | 2023 | |
| Alexion Pharmaceuticals, INC. | $18.82 | 2020 | |
| Fresenius Kabi USA, LLC | $17.66 | 2023 | Idacio |
| Medexus Pharma, INC. | $14.28 | 2019 | |
| Eyevance Pharmaceuticals LLC | $14.04 | 2021 | |
| Hikma Pharmaceuticals USA | $14.04 | 2021 | |
| Organon LLC | $13.99 | 2023 | Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Crawford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.